Loading
A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by Biohaven Therapeutics Ltd., now recruiting.
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors. ClinicalTrials.gov record last updated 2026-09-28: recruiting. Enrollment is planned at 500 participants. Primary completion is estimated at 2028-02. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: BHV-1510, Cemiplimab, BHV-1510, BHV-1510, Cemiplimab. Registered primary measures: Phase 1: Number of patients with adverse events (AEs); Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD); Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BHV-1510, TROP2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Cemiplimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares TROP2, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/